<div id="readability-page-1">Bioventus (BVS) is up  ~19% in Tuesday trading after posting Q3 financial results that beat on both lines.  While net sales change year-over-year was essentially flat due to a ~29% decline in its restorative therapies segment, the medical device company saw strong growth of, respectively, 6.4% and 9.3%, in its two largest businesses, pain treatment...</div>

<p>Bioventus (BVS) shares surged approximately 19% following the release of its Q3 financial results, which exceeded expectations. Despite a year-over-year net sales change that remained flat due to a significant 29% decline in the restorative therapies segment, the company experienced notable growth of 6.4% and 9.3% in its two largest sectors, pain treatment and another unspecified area.</p>

Bioventus surges on Q3 beats